Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Respiratory Tract Diseases AND Thoracic Diseases

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    759 result(s) found for: Respiratory Tract Diseases AND Thoracic Diseases. Displaying page 6 of 38.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2014-002590-10 Sponsor Protocol Number: P130906 Start Date*: 2016-02-11
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Effect of bronchodilators on effort induced dyspnoea in patients suffering lung hypertension
    Medical condition: Idiopathic or heritable patients with pulmonary arterial hypertension (PAH).
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-001139-22 Sponsor Protocol Number: POPH Start Date*: 2011-06-29
    Sponsor Name:Medizinische Universität Graz, Klin. Abteilung für Gastroenterologie und Hepatologie
    Full Title: AMBRISENTAN FOR TREATMENT OF PORTOPULMONARY HYPERTENSION (POPH): A PILOT STUDY
    Medical condition: Portopulmonary Hypertension (PoPH) and Hepatopulmonary Syndrome HPS are present in a considerable number of patients with compensated cirrhosis. Treatment of PoPH with ambrisentan is well tolerated...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10067281 Portopulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000822-24 Sponsor Protocol Number: VP-C21-005 Start Date*: 2020-07-06
    Sponsor Name:Vicore Pharma AB
    Full Title: A Phase 2, Multi-Centre, Open-Label, Single-Arm Trial Investigating the Safety, Efficacy and Pharmacokinetics of C21 in Subjects with Idiopathic Pulmonary Fibrosis
    Medical condition: Idiopathic Pulmonary Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2013-001490-25 Sponsor Protocol Number: 3/016/13 Start Date*: 2013-08-08
    Sponsor Name:University of Aberdeen [...]
    1. University of Aberdeen
    2. NHS Grampian
    Full Title: A randomised, double-blind placebo controlled trial of the effectiveness of low dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pu...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    16.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-003771-34 Sponsor Protocol Number: D9180C00004 Start Date*: 2022-01-13
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants ...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002389-29 Sponsor Protocol Number: PULSE-COPD-007 Start Date*: 2016-07-25
    Sponsor Name:Bellerophon Pulse Technologies, LLC
    Full Title: An Exploratory Clinical Study to Assess the Effect of Pulsed, Inhaled Nitric Oxide (iNO) on Functional Respiratory Imaging (FRI) Parameters in Subjects with World Health Organization (WHO) Group 3 ...
    Medical condition: Pulmonary Hypertension (PH) Associated with Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037401 Pulmonary hypertensions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004297-98 Sponsor Protocol Number: 117113 Start Date*: 2014-09-01
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Study 117113: Mepolizumab vs. Placebo as add-on treatment for frequently exacerbating COPD patients characterized by eosinophil level.
    Medical condition: Treatment of severe Chronic Obstructive Pulmonary Disease (COPD) in patients presenting frequent exacerbations
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) SK (Completed) DE (Completed) GB (Completed) DK (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2018-001590-24 Sponsor Protocol Number: 01.01.18 Start Date*: 2019-03-21
    Sponsor Name:University of Dundee [...]
    1. University of Dundee
    2. NHS Tayside
    Full Title: A Trial of the Safety, Tolerability and Efficacy of 2 doses of Cayston (Aztreonam Lysine) compared to placebo in participants with bronchiectasis.
    Medical condition: Bronchiectasis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038738 - Respiratory, thoracic and mediastinal disorders 10006445 Bronchiectasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2019-001160-29 Sponsor Protocol Number: NAL-II-19-1 Start Date*: 2019-06-24
    Sponsor Name:LABORATOIRES SMB S.A
    Full Title: A single blind, placebo controlled, three period, chronic dosing (6 weeks), multicentre, exploratory study to evaluate the effects of Nacystelyn (20 mg BID and 40 mg BID) on Functional Respiratory ...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004870-26 Sponsor Protocol Number: CQVA149ADE01 Start Date*: 2012-03-27
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 26-week treatment, multicenter, randomized, parallel group, blinded study to assess the efficacy and safety of QVA149 (110/50 µg q.d.) in patients with moderate to severe chronic obstructive pulm...
    Medical condition: chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002632-75 Sponsor Protocol Number: CLI-050000-04 Start Date*: 2020-07-08
    Sponsor Name:CHIESI FARMACEUTICI S.p.A
    Full Title: Multicenter, open-label, randomised trial to assess the efficacy and tolerability of poractant alfa (porcine surfactant, Curosurf®) in hospitalized patients with SARS-COV-19 acute respiratory distr...
    Medical condition: patients with SARS-COV-19 acute respiratory distress syndrome (ARDS)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-000279-38 Sponsor Protocol Number: ENDOSC-CLAD Start Date*: 2022-11-03
    Sponsor Name:FUNDACION INVESTIGACION BIOMEDICA HOSPITAL PUERTA DE HIERRO MAJADAHONDA
    Full Title: AN OPEN LABEL, RANDOMISED, CONTROLLED CLINICAL TRIAL TO ASSESS THE SAFETY OF ENDOBRONCHIAL ADMINISTRATION OF ALLOGENEIC MESENCHYMAL STROMAL CELLS IN PATIENTS WITH LUNG TRANSPLANT CHRONIC REJECTION:...
    Medical condition: PATIENTS WITH LUNG TRANSPLANT CHRONIC REJECTION
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038738 - Respiratory, thoracic and mediastinal disorders 10083303 Bronchiolitis obliterans syndrome PT
    21.1 10021428 - Immune system disorders 10051604 Lung transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004659-37 Sponsor Protocol Number: 1237.13 Start Date*: 2012-03-01
    Sponsor Name:SCS Boehringer Ingelheim Comm.V
    Full Title: A randomised, double-blind, 5 treatment arms, 4-period, incomplete cross-over study to determine the effect of 6 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (F...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009032 Chronic obstructive lung disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004660-30 Sponsor Protocol Number: 1237.14 Start Date*: 2012-01-18
    Sponsor Name:Boehringer Ingelheim b.v.
    Full Title: A randomised, double-blind, 5 treatment arms, 4-period, incomplete cross-over study to determine the effect of 6 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (F...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009032 Chronic obstructive lung disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) SE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2022-002677-29 Sponsor Protocol Number: 4739 Start Date*: 2023-01-11
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA DI FERRARA
    Full Title: Correlating Inflammatory Values of FEno, SymToms, SpuTum and Lung Function in Asthma
    Medical condition: Asthma, a chronic inflammatory disease of the airways, is characterized by a variability of symptoms that can evolve in an acute and sometimes severe form. Treatment of asthma involves daily treatm...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10064823 Asthmatic crisis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-003712-20 Sponsor Protocol Number: SPON1451-15 Start Date*: 2016-09-05
    Sponsor Name:Cardiff University
    Full Title: A randomised, double blind, double-dummy, placebo controlled trial of inhaled treatment to establish the mechanisms of prematurity-associated airway obstruction and inflammation.
    Medical condition: prematurity-related airway obstruction and inflammation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10067775 Upper airway obstruction PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10006464 Bronchoconstriction LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-005914-12 Sponsor Protocol Number: DB2116133 Start Date*: 2012-08-08
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Randomized, Double-Blind, 3-Way, Cross-Over Study to Evaluate Lung Function Response after Treatment with Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg Once-Daily...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002806-30 Sponsor Protocol Number: PUL-042-402 Start Date*: 2018-12-14
    Sponsor Name:Pulmotect, Inc.
    Full Title: A Phase 2, Single-Center, Double-Blind, Placebo-Controlled, Study of PUL-042 Inhalation Solution in Rhinovirus-induced Symptoms in Current Smokers with Gold Stage 0 Chronic Obstructive Pulmonary Di...
    Medical condition: GOLD (Global Initiative for Chronic Obstructive Lung Disease) stage 0 Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2018-002631-15 Sponsor Protocol Number: BECRO/RESP/BREATH-PD Start Date*: 2018-09-04
    Sponsor Name:RESPIRENT Pharmaceuticals
    Full Title: A phase III, randomized, multicenter, parallel-group clinical trial for examining the therapeutic equivalence between Fluticasone propionate 100 mcg and salmeterol 50 mcg inhalation powder/Respiren...
    Medical condition: Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation. It is defined by the history of respiratory symptoms such as wheeze, shortness of breath, chest tightness an...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003555 Asthma bronchial LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003561 Asthma, unspecified LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003510-41 Sponsor Protocol Number: 200163 Start Date*: 2014-01-24
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A two part, Phase IIa, randomized, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical efficacy of oral danirixin (GSK1325756) in symp...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 10:30:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA